StockData

AbbVie vs Johnson & Johnson

ABBV and JNJ side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ABBV and JNJ compare

Johnson & Johnson is the larger company, worth 1.3 times as much as AbbVie ($680B against $521B).

On earnings, Johnson & Johnson is cheaper: it trades at 42.9× trailing earnings, against 83.2× for AbbVie.

AbbVie grew revenue faster over the last twelve months (10.4% versus 7.8% for Johnson & Johnson).

Johnson & Johnson keeps more of each dollar of sales as profit, with a net margin of 16.2% compared with 9.8% at AbbVie.

Both pay dividends: AbbVie yields 2.3% and Johnson & Johnson 1.9%.

Johnson & Johnson scores higher on the StockData Score (12 against 10 for AbbVie), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricABBVJNJ
Size and price
Market cap$521B$680B
Share price$294.55$282.55
Change, 1 year26.8%44.7%
Change, 5 years153%77.5%
Beta (5Y)−0.59−0.32
Employees57K138K
StockData Score
Total score1012 (better)
Valuation score00
Growth score33
Performance score24 (better)
Health score23 (better)
Dividend score3 (better)2
Valuation
P/E83.2×42.9× (better)
P/S8.1×6.8× (better)
P/B–8.3×
EV/EBITDA34.7×26.4× (better)
P/FCF28.6× (better)33.0×
PEG–2.40
FCF yield3.5% (better)3.0%
Fair value$154.71$150.46
Margin of safety−90.4%−87.8% (better)
Growth
Revenue growth (TTM)10.4% (better)7.8%
Revenue growth, 5Y average6.0% (better)2.7%
Net income growth (TTM)67.7% (better)−35.9%
EPS growth (TTM)68.6% (better)−36.4%
EPS growth, 5Y average−2.8%14.9% (better)
Profitability
Gross margin71.5% (better)67.6%
Operating margin26.2%–
Net margin9.8%16.2% (better)
FCF margin28.3% (better)20.7%
Return on equity–20.0%
Return on invested capital20.1%–
Financial health
Debt / equity–0.55
Net debt / EBITDA3.811.02 (better)
Interest coverage5.8×–
Current ratio0.811.02 (better)
Altman Z-score2.855.22 (better)
Piotroski F-score8 (better)4
Dividends and buybacks
Dividend yield2.3% (better)1.9%
Payout ratio190%–
Years of dividend growth1116 (better)
Dividend growth, 5Y average6.6% (better)5.2%
Buyback yield0.29%1.2% (better)
Shareholder yield2.6%3.0% (better)
Ownership
Held by institutions75.6%74.8%
Held by insiders0.09%0.04%
Insider net buying, 12 months−$30.8M (better)−$154M
Superinvestors holding36 (better)
Short interest, % of float0.90%0.71%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.